|
BMS-986504 Clinical Trials
8 actively recruiting trials across 5 locations
▲ +1 trial since July 2026
Also known as: MRTX1719, Navlimetostat
Pipeline
Early 1: 1Phase 1: 3Phase 2: 3Phase 2/3: 1
Top Sponsors
- Bristol-Myers Squibb5
- Nader Sanai1
- Memorial Sloan Kettering Cancer Center1
- M.D. Anderson Cancer Center1
Indications
- Cancer8
- Lung Cancer3
- Gastroesophageal Carcinoma1
- Diffuse Pleural Mesothelioma1
- MTAP-deleted Pancreatic Cancer1
Other2 trials
Anchorage, Alaska2 trials
Phoenix, Arizona1 trial
Clinical Trial of BMS-986504 in Recurrent GBM Patients
St. Joseph's Hospital and Medical Center
Early 1
San Francisco, California1 trial
Basking Ridge, New Jersey1 trial
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Phase 1
Houston, Texas1 trial
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
MD Anderson Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.